RAB25: A Potential Drug Target for Cancer and Other Diseases (G57111)

Target Name: RAB25

NCBI ID: G57111

RAB25

RAB25: A Potential Drug Target for Cancer and Other Diseases

RAB25 is a non-coding RNA molecule that is expressed in various tissues of the body. It is a member of the RAS oncogene family, which plays a crucial role in the development and progression of many diseases, including cancer. RAB25 has been identified as a potential drug target or biomarker, which could be used to develop new treatments for these diseases.

The RAS oncogene family

The RAS oncogene family is a group of non-coding RNA molecules that are characterized by the presence of a catalytic domain and a transmembrane region. These molecules are involved in the regulation of various cellular processes, including cell signaling, cell division, and cell survival. They are also involved in the development and progression of many diseases, including cancer.

RAB25 is a member of the RAS oncogene family and is expressed in various tissues of the body. It is a small non-coding RNA molecule that is made up of only 18 amino acid residues. RAB25 is primarily expressed in the brain, heart, and kidneys, and has been shown to be involved in the regulation of various cellular processes, including cell signaling, cell division, and cell survival.

Drug targeting RAB25

RAB25 has been identified as a potential drug target or biomarker because of its involvement in the regulation of cellular processes that are associated with the development and progression of many diseases. For example, RAB25 has been shown to be involved in the regulation of cell signaling, which is involved in the development and progression of many diseases, including cancer.

In addition, RAB25 has also been shown to be involved in the regulation of cell division, which is also involved in the development and progression of many diseases. For example, RAB25 has been shown to be involved in the regulation of cell proliferation, which is involved in the development and progression of many diseases, including cancer.

Another potential mechanism by which RAB25 may be targeted as a drug is its role in the regulation of cellular processes that are involved in the development and progression of diseases. For example, RAB25 has been shown to be involved in the regulation of inflammation, which is involved in the development and progression of many diseases, including cancer.

Conclusion

In conclusion, RAB25 is a non-coding RNA molecule that is expressed in various tissues of the body and is a member of the RAS oncogene family. It has been identified as a potential drug target or biomarker due to its involvement in the regulation of various cellular processes that are associated with the development and progression of many diseases. Further research is needed to determine the full extent of RAB25's role in the regulation of cellular processes and to develop new treatments based on this information.

Protein Name: RAB25, Member RAS Oncogene Family

Functions: Involved in the regulation of cell survival. Promotes invasive migration of cells in which it functions to localize and maintain integrin alpha-V/beta-1 at the tips of extending pseudopodia (PubMed:17925226). Involved in the regulation of epithelial morphogenesis through the control of CLDN4 expression and localization at tight junctions (By similarity). May selectively regulate the apical recycling pathway. Together with MYO5B regulates transcytosis (By similarity)

The "RAB25 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RAB25 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets